Replies to post #218740 on Biotech Values

[jondoeuk]

The biggest problem is going to be neoantigen identification. I can't see the approaches that are used by Dr. Ji or Gritstone Oncology going to be a major improvement upon the current in silico versions (I hope I'm wrong).

[DewDiligence]

ADRO CMO leaves for no stated reason:

https://globenewswire.com/news-release/2018/09/19/1573123/0/en/Aduro-Biotech-Announces-the-Departure-of-Natalie-R-Sacks-M-D.html